Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/6/2008

DALLAS, Nov. 6 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Rodman & Renshaw Annual Global Investment Conference to be held November 10-12, 2008 at the New York Palace Hotel. Jeffrey B. Davis, CEO of Access is scheduled to speak on Tuesday, November 11, 2008 at 2:50 p.m. Eastern Time, and will give a corporate overview and discuss the Company's product opportunities.

The presentation will be available via webcast and can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob. The replay can be obtained at the same link for 90 days.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include Prodac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
6. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
11. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Calif. , Jan. 23, 2017  Alkahest ... innovative treatments for neurodegenerative diseases and other age-related ... joined the company as Chief Medical Officer. In ... and clinical development activities at Alkahest and serve ... Jackson most recently served as Executive Director at ...
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
Breaking Biology News(10 mins):